Detalles de la búsqueda
1.
Comparative assessment of viral dynamic models for SARS-CoV-2 for pharmacodynamic assessment in early treatment trials.
Br J Clin Pharmacol
; 88(12): 5428-5433, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36040430
2.
A Comprehensive Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Drug Interactions of Nirmatrelvir/Ritonavir.
Clin Pharmacokinet
; 63(1): 27-42, 2024 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38177893
3.
Dosing recommendation of nirmatrelvir/ritonavir using an integrated population pharmacokinetic analysis.
CPT Pharmacometrics Syst Pharmacol
; 12(12): 1897-1910, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37803876
4.
Use of modelling and simulation techniques to support decision making on the progression of PF-04878691, a TLR7 agonist being developed for hepatitis C.
Br J Clin Pharmacol
; 73(1): 77-92, 2012 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-21689140
5.
Pharmacokinetics of Oral Nirmatrelvir/Ritonavir, a Protease Inhibitor for Treatment of COVID-19, in Subjects With Renal Impairment.
Clin Pharmacol Ther
; 112(4): 892-900, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35712797
6.
Population Pharmacokinetic Modeling and Probability of Pharmacodynamic Target Attainment for Ceftazidime-Avibactam in Pediatric Patients Aged 3 Months and Older.
Clin Pharmacol Ther
; 111(3): 635-645, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34687548
7.
The use of the SAEM algorithm in MONOLIX software for estimation of population pharmacokinetic-pharmacodynamic-viral dynamics parameters of maraviroc in asymptomatic HIV subjects.
J Pharmacokinet Pharmacodyn
; 38(1): 41-61, 2011 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-21088872
8.
Pregabalin Population Pharmacokinetic and Exposure-Response Analyses for Focal Onset Seizures in Children (4-16 years) and Adults, to Support Dose Recommendations in Children.
Clin Pharmacol Ther
; 110(1): 132-140, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33280106
9.
Pharmacokinetic and Pharmacodynamic Target Attainment in Adult and Pediatric Patients Following Administration of Ceftaroline Fosamil as a 5-Minute Infusion.
Clin Pharmacol Drug Dev
; 10(4): 420-427, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33465279
10.
The use of extrapolation based on modeling and simulation to support high-dose regimens of ceftaroline fosamil in pediatric patients with complicated skin and soft-tissue infections.
CPT Pharmacometrics Syst Pharmacol
; 10(6): 551-563, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33687148
11.
Comparing Model Performance in Characterizing the PK/PD of the Anti-Myostatin Antibody Domagrozumab.
Clin Transl Sci
; 13(1): 125-136, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31550073
12.
Phase 2 Study of the Safety, Pharmacokinetics and Efficacy of Ceftaroline Fosamil in Neonates and Very Young Infants With Late-onset Sepsis.
Pediatr Infect Dis J
; 39(5): 411-418, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32091493
13.
No Clinical Impact of CYP3A5 Gene Polymorphisms on the Pharmacokinetics and/or Efficacy of Maraviroc in Healthy Volunteers and HIV-1-Infected Subjects.
J Clin Pharmacol
; 59(1): 139-152, 2019 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30192390
14.
A population pharmacokinetic meta-analysis of maraviroc in healthy volunteers and asymptomatic HIV-infected subjects.
Br J Clin Pharmacol
; 65 Suppl 1: 76-85, 2008 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-18333869
15.
Levodopa slows progression of Parkinson's disease: external validation by clinical trial simulation.
Pharm Res
; 24(4): 791-802, 2007 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-17308968
16.
Disease progression and pharmacodynamics in Parkinson disease - evidence for functional protection with levodopa and other treatments.
J Pharmacokinet Pharmacodyn
; 33(3): 281-311, 2006 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-16625427
17.
Importance of within subject variation in levodopa pharmacokinetics: a 4 year cohort study in Parkinson's disease.
J Pharmacokinet Pharmacodyn
; 32(3-4): 307-31, 2005 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-16320098
18.
Pharmacokinetic and pharmacodynamic changes during the first four years of levodopa treatment in Parkinson's disease.
J Pharmacokinet Pharmacodyn
; 32(3-4): 459-84, 2005 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-16320101
19.
Modeling the short- and long-duration responses to exogenous levodopa and to endogenous levodopa production in Parkinson's disease.
J Pharmacokinet Pharmacodyn
; 31(3): 243-68, 2004 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-15518246
Resultados
1 -
19
de 19
1
Próxima >
>>